Cargando…
Pexmetinib suppresses osteoclast formation and breast cancer induced osteolysis via P38/STAT3 signal pathway
Breast cancer metastases to the bone can lead to a series of bone-related events that seriously affect the quality of life. Pexmetinib, a novel p38 mitogen-activated protein kinase (p38) inhibitor that has been evaluated in phase I clinical trials for myelodysplastic syndrome, but the effects of Pex...
Autores principales: | Jie, Zhiwei, Wang, Shiyu, Ma, Qingliang, Shen, Yang, Zhao, Xiangde, Yu, Hejun, Xie, Ziang, Jiang, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253705/ https://www.ncbi.nlm.nih.gov/pubmed/35800294 http://dx.doi.org/10.1016/j.jbo.2022.100439 |
Ejemplares similares
-
Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells
por: Wang, Qiang, et al.
Publicado: (2018) -
Kaempferide Prevents Titanium Particle Induced Osteolysis by Suppressing JNK Activation during Osteoclast Formation
por: Jiao, Zixian, et al.
Publicado: (2017) -
Osteoclasts; culprits in inflammatory osteolysis
por: Teitelbaum, Steven L
Publicado: (2006) -
Phillyrin Attenuates Osteoclast Formation and Function and Prevents LPS-Induced Osteolysis in Mice
por: Wang, Jing, et al.
Publicado: (2019) -
Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis
por: Jung, Youn-Kwan, et al.
Publicado: (2019)